Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 901–1,000 of 1,003
Ghrelin and peptide YY in postpartum lactating and nonlactating women
Larson‐Meyer, D. E., Ravussin, É., Heilbronn, L. K., & de Jonge, L. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28616 · Cited by 17
“As previously shown in other populations (9, 12, 34, 35), we found that basal ghrelin but not PYY is downregulated with increasing adiposity in postpartum women, regardless of lactation status.”
BackgroundMethodResultExercise and Weight Loss: What Is the Evidence of Sex Differences?
Hagobian, T. A., & Evero, N. (2012) · Current Obesity Reports · doi:10.1007/s13679-012-0035-6 · Cited by 23
“Peripheral infusion of PYY3-36 (active form of PYY) decreases energy intake in animals and humans [32–34].”
BackgroundGastrointestinal regulatory peptides and their effects on fat tissue
Majumdar, I. D., & Weber, H. C. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833327dd · Cited by 18
Formichi, C., Caprio, S., Nigi, L., & Dotta, F. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103975 · Cited by 20
Metabolic Changes Following Smoking Cessation in Patients with Type 2 Diabetes Mellitus
Driva, S., Korkontzelou, A., Tonstad, S., Tentolouris, N., Litsiou, E., Vasileiou, V., Vassiliou, A. G., Saltagianni, V., & Katsaounou, P. A. (2024) · Biomedicines · doi:10.3390/biomedicines12081882 · Cited by 20
“Previous studies have demonstrated that PYY can positively influence lipid profiles by decreasing levels of atherogenic lipoproteins such as LDL-C [76].”
Metformin in gestational diabetes: physiological actions and clinical applications
Mason, T., Alesi, S., Fernando, M., Vanky, E., Teede, H. J., & Mousa, A. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01049-w · Cited by 20
“Indeed, ghrelin has been shown to supress PYY 43 and vice versa, with PYY suppressing ghrelin when infused in a fasted state among individuals with obesity and normal weight 44 , supporting a reciprocal ghrelin–PYY regulatory mechanism.”
Brissette, C., Jenkins, A. L., Choleva, L., & Vuksan, V. V. V. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.183 · Cited by 24
Neuroendocrine Control of Food Intake
Park, S. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.6.391 · Cited by 16
Gelegen, Ç., Chandarana, K., Choudhury, A. I., Al‐Qassab, H., Evans, I. M., Irvine, E. E., Hyde, C., Claret, M., Andréelli, F., Sloan, S. E., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00033.2012 · Cited by 20
“5 in the part of the brain covering mesencephalon to myelencephalon, and its level changed significantly at various developmental stages [F (5,28) 34.”
BackgroundInfluentialSelf-citationCagiltay, E., Çelik, A., Dixon, J. B., Pouwels, S., Santoro, S., Gupta, A., Ugale, S. M., & Abdul‐Ghani, M. A. (2019) · Diabetic Medicine · doi:10.1111/dme.14191 · Cited by 17
Larsen, A. T., Sonne, N., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.263400 · Cited by 17
“This underlines that the improved food preference is independent of the lean/obese state and, thereby, potential differences in appetite regulatory hormones (Tschöp et al., 2001; Batterham et al., 2003; Steinert et al., 2017).”
BackgroundInfluentialAbbasi, M. M., & Farhangi, M. A. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.37 · Cited by 16
“The circulating PYY3-36 as the predominant form is a major endocrine mediator of satiation and reduces body weight and its deficiency is a potent inducer of obesity (19, 20).”
BackgroundWeise, C. M., Thiyyagura, P., Reiman, E. M., Chen, K., & Krakoff, J. A. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.12.023 · Cited by 17
“Importantly, obese individuals do not appear to develop a resistance to the anorectic effects of PYY as occurs with the adipokine leptin (Batterham et al., 2003).”
BackgroundRecompensa alimentar: mecanismos envolvidos e implicações para a obesidade
Ribeiro, G., & Santos, O. (2013) · Endocrinology Insights · doi:10.1016/j.rpedm.2013.09.001 · Cited by 49
Palou, A., Bonet, M. L., Picó, C., & Rodríguez, A. M. (2017) · Revista de medicina de la Universidad de Navarra · doi:10.15581/021.7462 · Cited by 31
Role of Surgery in Management of Type 2 Diabetes Mellitus
Herron, D. M., & Tong, W. W. Y. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20114 · Cited by 20
White, N. E., Dhillo, W. S., Liu, Y. ‐., Small, C. J., Kennett, G. A., Gardiner, J., Ghatei, M. A., & Bloom, S. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00807.x · Cited by 16
Self-citationEnergy Intake during a Typical Himalayan Trek
Major, G. C., & Doucet, É. (2004) · High Altitude Medicine & Biology · doi:10.1089/ham.2004.5.355 · Cited by 16
“…peptides involved in the regulation of meal size and/or frequency, such as ghrelin (Cummings et al., 2001; Wren et al., 2001), peptide yy3-36 (Batterham et al., 2003), and oxyntomodulin (Cohen et al., 2003), to name but a few, also play a significant role in the changes in appetite and EI…”
Torsello, A., Brambilla, F., Tamiazzo, L., Bulgarelli, I., Rapetti, D., Bresciani, E., & Locatelli, V. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03349245 · Cited by 19
Peptide YY3–36 and Satiety: Clarity or Confusion?
Coll, A. P., Challis, B., & O’Rahilly, S. (2004) · Endocrinology · doi:10.1210/en.2004-0342 · Cited by 16
Johnstone, A. M. (2013) · Elsevier eBooks · doi:10.1533/9780857098719.3.128 · Cited by 18
Oesch, S., Degen, L. P., & Beglinger, C. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00039.2005 · Cited by 15
“Other gastrointestinal peptides that have been associated with nutrient stimulated inhibition of food intake include glucagonlike peptide-1 (GLP-1) and peptide YY (PYY 3-36) (3, 11).”
BackgroundPostpyloric Gastrointestinal Peptides
Englander, E. W., & Greeley, G. H. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50008-8 · Cited by 19
Nutrient‐sensing components of the mouse stomach and the gastric ghrelin cell
Nunez‐Salces, M., Li, H., Feinle‐Bisset, C., Young, R. L., & Page, A. J. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13944 · Cited by 18
Yunker, A. G., LUO, S. H., Jones, S., Dorton, H. M., Alves, J. M., ANGELO, B. C., DEFENDIS, A. W., Pickering, T. A., Monterosso, J. R., & Page, K. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa865 · Cited by 17
Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis
Ding, H., Zhang, Y., Ma, X., Zhang, Z., Xu, Q., Liu, C., Li, B., Dong, S., Li, L., Zhu, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016635 · Cited by 16
“The main effects of PYY involve the central regulation of appetite as well as the regulation of blood glucose homeostasis (Batterham et al., 2003).”
BackgroundKhoury, D. T. D. E., & Hwalla, N. C. (2010) · Annals of Nutrition and Metabolism · doi:10.1159/000317343 · Cited by 17
“increase after meal ingestion, and induce satiety when peripherally injected [”
BackgroundMahaut, S., Dumont, Y., Fournier, A., Quirion, R., & Moyse, E. (2009) · Neuropeptides · doi:10.1016/j.npep.2009.10.001 · Cited by 15
“In fact, increased levels of PYY3- 36 and PP in blood circulation resulted in a reduction of food intake in several species ( Batterham et al., 2003a, b; Jesudason et al., 2007;”
BackgroundPotential therapies based on antidiabetic peptides
Billyard, T., McTernan, P. G., & Kumar, S. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.006 · Cited by 21
The Metabolic Effects of Laparoscopic Sleeve Gastrectomy: A Review
Noah, J., Smith, A. I., Birch, D. W., & Karmali, S. (2013) · Journal of Minimally Invasive Surgical Sciences · doi:10.5812/jmiss.7319 · Cited by 17
When gut fermentation controls satiety: A PYY story
Burcelin, R. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.005 · Cited by 16
“In addition to GLP-1, PYY is another enteroendocrine peptide secreted by the L cells and involved in the control of body weight gain [5].”
Sanches, E. E., Timmermans, M., Topal, B., Çelik, A., Sundbom, M., Ribeiro, R. J. D. S., Parmar, C. D., Ugale, S. M., Proczko, M., Stepaniak, P. S., et al. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1690991 · Cited by 16
“The same anorectic effects of PYY3-36 were found in obese subjects [117].”
BackgroundAdiponectin and peptide YY in the fasting blue fox (Alopex lagopus)
Mustonen, A., Pyykönen, T., & Nieminen, P. (2005) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpb.2005.01.003 · Cited by 15
Peters, H. P. F., & Mela, D. J. (2008) · CRC Press eBooks · doi:10.1201/9781420047844.ch10 · Cited by 16
Rubio, I. G. S., Castro, G., Zanini, A. C., & Medeiros-Neto, G. A. (2008) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/bf03327784 · Cited by 20
“Furthermore, PYY infusion reduces cumulative 24 hours food intake both in lean subjects and obese patients (6).”
BackgroundDietary Synergies in Appetite Control: Distal Gastrointestinal Tract
Woods, S. C. (2006) · Obesity · doi:10.1038/oby.2006.301 · Cited by 15
Obesity: A Peptide YY-Deficient, But Not Peptide YY- Resistant, State
Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2005-1217 · Cited by 15
The Association of Peptide Hormones with Glycemia, Dyslipidemia, and Obesity in Lebanese Individuals
Abou-Samra, M., Venema, K., Moubareck, C. A., & Karavetian, M. (2022) · Metabolites · doi:10.3390/metabo12111051 · Cited by 14
Holst, J. J., Madsbad, S., Bojsen-Møller, K. N., Dirksen, C., & Svane, M. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171199 · Cited by 18
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“161 Preclinical data have demonstrated a reduction in body weight and modulation of food intake during treatment with NPY2R agonists.”
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 17
Self-citationGut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Will, S., Hornigold, D. C., Baker, D. J., Coghlan, M. P., Mesquita, M., Trevaskis, J. L., & Naylor, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.010 · Cited by 16
Wysokiński, A., & Łucka, A. (2019) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_29_19 · Cited by 15
“In contrast, PYY(3-36) has anorexigenic properties by high affinity for the Y2-receptor subtype and some affinity for the Y1- and Y5-receptor subtypes.[29] PYY secretion is regulated in proportion to the calories consumed by food (mainly high-fat meals).”
BackgroundCrabtree, D. R., Buosi, W., Fyfe, C., Horgan, G. W., Μanios, Y., Androutsos, O., Giannopoulou, A., Finlayson, G., Beaulieu, K., Meek, C. L., et al. (2020) · Nutrients · doi:10.3390/nu12123710 · Cited by 15
Gastrointestinal hormones and polycystic ovary syndrome
Ma, J., Lin, T. C., & Liu, W. (2014) · Endocrine · doi:10.1007/s12020-014-0275-1 · Cited by 15
Fällmar, H., Åkerberg, H., Gutiérrez‐de‐Terán, H., Lundell, I., Mohell, N., & Larhammar, D. (2011) · Neuropeptides · doi:10.1016/j.npep.2011.05.006 · Cited by 14
“This finding was later confirmed in obese humans (Batterham et al., 2003) and resulted in increased interest in the Y2 receptor as a potential anti-obesity target.”
ResultPedersen, S. L., Sasikumar, P. G., Chelur, S., Holst, B., Artmann, A., Jensen, K. J., & Vrang, N. (2010) · Journal of Peptide Science · doi:10.1002/psc.1281 · Cited by 14
Hyland, N. P., Pittman, Q. J., & Sharkey, K. A. (2007) · Peptides · doi:10.1016/j.peptides.2007.03.011 · Cited by 14
Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats
Nadkarni, P. P., Costanzo, R. M., & Sakagami, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01363.x · Cited by 14
Pancreatic Polypeptide Meal Response May Predict Gastric Band-Induced Weight Loss
Dixon, A. F. R., le Roux, C. W., Ghatei, M. A., Bloom, S. R., McGee, T. L., & Dixon, J. B. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0469-z · Cited by 14
Self-citationLow-carbohydrate diet disrupts the association between insulin resistance and weight gain
Leite, J. O. M., deOgburn, R. C., Ratliff, J. C., Su, R., Volek, J. S., McGrane, M. M., Dardik, A., & Fernández, M. L. (2009) · Metabolism · doi:10.1016/j.metabol.2009.04.004 · Cited by 15
Nguo, K., Walker, K. Z., Bonham, M. P., & Huggins, C. E. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.256 · Cited by 17
Park, E., Edirisinghe, I., Inui, T., Miquel-Kergoat, S., Kelley, M., & Burton‐Freeman, B. M. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.03.002 · Cited by 15
Rigamonti, A. E., Bini, S., Rocco, M. C., Giardini, V., Massimini, D., Crippa, M. G., Saluzzi, A., Casati, M., Marazzi, N., Perotti, M., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0933-6 · Cited by 14
Excess pregnancy weight gain in latinas: Impact on infant’s adiposity and growth hormones at birth
Elwan, D., Olveda, R., Medrano, R., & Wojcicki, J. M. (2021) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2021.101341 · Cited by 14
Mechanisms of the metabolic syndrome
Mehta, N. N., & Reilly, M. P. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.09.010 · Cited by 20
Vagenas, K., Panagiotopoulos, S., Kehagias, I., Karamanakos, S. N., Mead, N., & Kalfarentzos, F. E. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6024 · Cited by 14
Mönkäre, J., Hakala, R. A., Kovalainen, M., Korhonen, H., Herzig, K., Seppälä, J. V., & Järvinen, K. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.09.011 · Cited by 18
Gut feeling – the secret of satiety?
Bloom, S. R., Wynne, K., & Chaudhri, O. B. (2005) · Clinical Medicine · doi:10.7861/clinmedicine.5-2-147 · Cited by 14
Self-citationPhysiology: Does gut hormone PYY3–36 decrease food intake in rodents?
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02666a · Cited by 14
Self-citationObesity Epidemic in the United States
Hunsaker, D. M., & Hunsaker, J. C. (2005) · Humana Press eBooks · doi:10.1385/1-59259-872-2:061 · Cited by 14
An overview of the central control of weight regulation and the effect of antipsychotic medication
Tighe, S., & Dinan, T. G. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058679 · Cited by 16
“Another satiety mediator is PYY3–36 which is released by the GI tract and exerts its activity centrally by binding to pre-synaptic inhibitory Y2 receptors, and thus reducing NPY activity (Batterham et al., 2003).”
BackgroundThe Role of Somatostatin in the Gastrointestinal Tract
Papantoniou, K., Aggeletopoulou, I., Pastras, P., & Triantos, C. K. (2025) · Biology · doi:10.3390/biology14050558 · Cited by 22
“PYY reduces appetite and is associated with conditions such as obesity and anorexia nervosa [80].”
Gut peptides before and following Roux‐En‐Y gastric bypass: A systematic review and meta‐analysis
Simoneau, M., McKay, B., Brooks, E., Doucet, É., & Baillot, A. (2024) · Obesity Reviews · doi:10.1111/obr.13702 · Cited by 14
van de Sande‐Lee, S., Cardoso, A. R., Garlipp, C. R., Chaim, É. A., Pareja, J. C., Geloneze, B., & Velloso, L. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.70 · Cited by 14
The Effect of a 20 km Run on Appetite Regulation in Long Distance Runners
Kojima, C., Ishibashi, A., Ebi, K., & Goto, K. (2016) · Nutrients · doi:10.3390/nu8110672 · Cited by 13
Kowalka, A. M., Αλεξιάδου, Κ., Cuenco, J., Clarke, R. E., MINNION, J. S., Williams, E. L., Bech, P., Purkayastha, S., Ahmed, A., Takáts, Z., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14846 · Cited by 13
“It has been reported that obese patients have lower fasting plasma PYY concentrations and a reduced secretion of PYY after eating.(8) We used the LC‐MS/MS assay to study PYY dynamics after an MMT TABLE 1 Details of MRM transitions used for quantification of PYY compounds and corresponding internal standards (IS).”
MethodResultInfluentialSelf-citationBornath, D. P. D., McKie, G. L., McCarthy, S. F., Vanderheyden, L. W., Howe, G. J., Medeiros, P. J., & Hazell, T. J. (2023) · Obesity · doi:10.1002/oby.23841 · Cited by 14
“Peptide secretion is strongly influenced by nutrients in the gastrointestinal tract [8]; however, individuals with OB display dysregulation in fasted and postprandial synthesis/secretion compared with normal weight (NW) individuals [6, 7, 9].”
BackgroundHigh expression of NPY receptors in the human testis
Körner, M., Waser, B., Thalmann, G. N., & Reubil, J. C. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.01.021 · Cited by 13
Gastrointestinal Issues in the Older Female Patient
Zuchelli, T. E., & Myers, S. E. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.03.007 · Cited by 14
Homan, P., Grob, S., Milos, G. F., Schnyder, U., & Hasler, G. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.12.024 · Cited by 14
“In support of this possibility, PYY infusion significantly decreased plasma ghrelin levels (Batterham et al., 2003) and a negative correlation of PYY with ghrelin has been reported by Kojima et al.”
BackgroundMcMillan, C. J., Zapata, R. C., Chelikani, P. K., Snead, E. C. R., & Cosford, K. (2015) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2015.10.001 · Cited by 18
Y5 receptor signalling counteracts the anorectic effects of PYY 3‐36 in diet‐induced obese mice
Shi, Y., Ip, C. K., Reed, F. M., Sarruf, D. A., Wulff, B. S., & Herzog, H. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12483 · Cited by 14
Vassallo, J. (2007) · OAR@UM (University of Malta) · Cited by 17
Yang, P., Cheng, M., Yang, W., Tsai, M., Lee, P., Chen, C., Lin, M., & Tseng, P. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3558-4 · Cited by 14
Näätänen, M., Kolehmainen, M., Laaksonen, D. E., Herzig, K., Poutanen, K. S., & Karhunen, L. J. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02438-3 · Cited by 16
Stephan, M., Radicke, A., Leutloff, S., Schmiedl, A., Pabst, R., von Hörsten, S., Dettmer, S., Lotz, J., & Nave, H. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.09.024 · Cited by 14
Gut peptide hormones: Importance for food intake
Näslund, E. B., Schmidt, P. T., & Hellström, P. M. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410010634 · Cited by 13
“However, its truncated form, PYY3-36, may act as an anorexigenic substance, as it is released together with GLP-1 from L-cells of the GI tract after a meal and induces satiety [92].”
BackgroundTai, K., Hammond, A. J., Wishart, J. M., Horowitz, M., & Chapman, I. M. (2010) · Appetite · doi:10.1016/j.appet.2010.07.010 · Cited by 13
“, 2007) and PYY infusion (Batterham et al., 2003) suppress ghrelin in humans.”
BackgroundDevelopment of minimally invasive techniques for management of medically-complicated obesity
Rashti, F., Gupta, E., Ebrahimi, S., Shope, T. R., Koch, T. R., & Gostout, C. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13424 · Cited by 13
Kirchner, H., Guijarro, A. I., & Meguid, M. M. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3281e2c9e7 · Cited by 13
Wang, Y., & Zhang, C. (2009) · American Journal of Biomedical Sciences · doi:10.5099/aj090100056 · Cited by 14
Approaches to the pharmacological treatment of obesity
Salem, V., & Bloom, S. R. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.54 · Cited by 15
Self-citationPeptide YY (PYY)3–36 modulates thyrotropin secretion in rats
Oliveira, K. J., de Paula, G. S. M., Costa-e-Sousa, R. H., Souza, L. L., Moraes, D. C., Curty, F. H., & Pazos-Moura, C. C. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06784 · Cited by 15
“PYY3-36 inhibits food intake at plasma concentrations that are within the normal physiological range seen in man after meals ( Batterham et al. 2002, 2003 ) and therefore, a role for the hormone in central mediation of postprandial satiety signals has been proposed.”
BackgroundInfluentialNeurohormonal pathways regulating food intake and changes after Roux-en-Y gastric bypass
Orlando, F. A., Gonçalves, C. G., George, Z. M., Halverson, J. D., Cunningham, P. R., & Meguid, M. M. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.05.009 · Cited by 14
“[56] Batterham RL, Cohen MA, Bloom SR.”
BackgroundGut–brain communication: how does it stand after bariatric surgery?
Diniz, M. D. F. H. S., Passos, V. M. D. A., & Diniz, M. T. C. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000241676.63041.11 · Cited by 13
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“In the early 2000s, Batterham et al. provided the first evidence that PYY 3–36 effectively reduces food intake in animals and obese humans [125,126].”
Hao, L., Schlussel, Y., Fieselmann, K. N., Schneider, S., & Shapses, S. A. (2017) · Nutrients · doi:10.3390/nu9080869 · Cited by 12
Chowdhury, E. A., Richardson, J. D., Gonzalez, J. T., Tsintzas, K., Thompson, D., & Betts, J. A. (2019) · Obesity · doi:10.1002/oby.22452 · Cited by 14
“This appears to highlight that despite several investigations identifying different concentrations or patterns of response of appetite hormones in individuals with obesity (20-22,35-38), these regulatory hormones do not exhibit any adaptation to differing daily morning feeding regimens over this time scale.”
BackgroundVijayvargiya, P., Chedid, V. G., Wang, X., Atieh, J., Maselli, D. B., Burton, D. D., Clark, M. M., Acosta, A. J., & Camilleri, M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00140.2020 · Cited by 15
“One possibility is that the decreased peak in postprandial levels of PYY and GLP-1 previously observed in studies of obese individuals are associated with reduced satiety (1, 4).”
BackgroundSridhar, A., Khan, D., Flatt, P. R., Irwin, N., & Moffett, R. C. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130359 · Cited by 12
Dumiaty, Y., Underwood, B. M., Phy‐Lim, J., & Chee, M. J. S. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102427 · Cited by 13
“Intravenous administration of PYY 3 – 36 reduced food intake by 30% in participants with obesity (Batterham et al., 2003; Degen et al., 2005), and this drop in food intake was accompanied by reports of increased fullness and reduced hunger (Sloth et al., 2007).”
BackgroundFiber intake Inconsistently Alters Gut Hormone Levels in Humans Following Acute or Chronic Intake
Klosterbuer, A. S., Greaves, K. A., & Slavin, J. L. (2012) · Journal of Food Research · doi:10.5539/jfr.v1n2p255 · Cited by 13
“Researchers have reported lower fasting and postprandial PYY concentrations in obese participants compared to lean individuals, and this is reversed following bariatric surgery (Batterham et al., 2003; le Roux et al., 2006).”
BackgroundWerling, M., Fändriks, L., Vincent, R. P., Cross, G. F., le Roux, C. W., & Olbers, T. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.04.018 · Cited by 13
“Obese patients have attenuated satiety and reduced GLP-1 and PYY responses in comparison to lean patients [16–18].”
MethodResultAntiobesity Effect of a Short-Length Peptide YY Analogue after Continuous Administration in Mice
Nishizawa, N., Niida, A., Masuda, Y., Kumano, S., Yokoyama, K., Hirabayashi, H., Amano, N., Ohtaki, T., & Asami, T. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00047 · Cited by 12
Neuropeptide Y – Its role in human performance and extreme environments
Kienast, C., Gunga, H., & Steinach, M. (2019) · REACH · doi:10.1016/j.reach.2019.100032 · Cited by 16
The Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
Gut hormone activity of children born to women with and without gestational diabetes
Chandler-Laney, P. C., Bush, N. C., Rouse, D. J., Mancuso, M., & Gower, B. A. (2013) · Pediatric Obesity · doi:10.1111/j.2047-6310.2012.00140.x · Cited by 12
“Furthermore, obesity has been consistently associated with suppression of the usual increase in PYY3–36 concentration that occurs following a meal (9,13,14).”
BackgroundInfluentialPYY in the Expanding Pancreatic Epithelium
Liu, G., Dabernat, S., Kritzik, M. R., Kayali, A. G., Zhang, Y.-Q., & Sarvetnick, N. (2006) · Endocrine · doi:10.1385/endo:30:1:103 · Cited by 12
Tackling obesity: new therapeutic agents for assisted weight loss
McFarlane, S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s6552 · Cited by 14
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.